Skip to main content

Idiopathic Inflammatory Myopathy

1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
CABA-201 following preconditioning with fludarabine and cyclophosphamidePhase 2/31 trial
Active Trials
NCT06154252Recruiting74Est. Jul 2028
Alliance Pharmaceuticals
1 program
A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory MyopathyN/A1 trial
Active Trials
NCT00971828Completed30Est. Sep 2012
Cabaletta Bio
Cabaletta BioPHILADELPHIA, PA
1 program
CABA-201 following preconditioning with fludarabine and cyclophosphamidePHASE_2_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BiocorpCABA-201 following preconditioning with fludarabine and cyclophosphamide
Alliance PharmaceuticalsA Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy

Clinical Trials (2)

Total enrollment: 104 patients across 2 trials

NCT06154252BiocorpCABA-201 following preconditioning with fludarabine and cyclophosphamide

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Start: Dec 2023Est. completion: Jul 202874 patients
Phase 2/3Recruiting
NCT00971828Alliance PharmaceuticalsA Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy

A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy

Start: Jul 2011Est. completion: Sep 201230 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 104 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.